Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: A case control study

Oncology

Volumn 78, Issue 1, 2010, Pages 20-25

  Panici, Pierluigi Benedetti ^a   Palaia, Innocenza ^a   Graziano, Marialida ^a   Bellati, Filippo ^a   Manci, Natalina ^a   Angioli, Roberto ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME   (Italy)

Author keywords

Consolidation chemotherapy; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CHLORPHENIRAMINE; METHYLPREDNISOLONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUNCTURE; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; YOUNG ADULT;

EID: 77949888525     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287968     Document Type: Article

References (30)

1. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95:S161-S192.
2. Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006; 33:S3-S11.
3. Gadducci A, Cosio S, Conte PF, et al: Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 2005; 55: 153-166.
4. Petit T, Velten M, d'Hombres A, et al: Longterm survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 2007; 104: 104-108.
5. Varia MA, Stehman FB, Bundy BN, et al: Intraperitoneal radioactive phosphorus ( 32 P) versus observation after negative secondlook laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 2849-2855.
6. Oei AL, Verheijen RH, Seiden MV, et al: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMGF1 without improvement in overall survival. Int J Cancer 2007; 120: 2710-2714.
7. Schilder RJ, Brady MF, Spriggs D, Shea T: Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2003; 88: 3-8.
8. Tournigand C, Louvet C, Molitor JL, et al: Long term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol 2003; 91: 341-345.
9. Barakat RR, Almadrones L, Venkatraman ES, et al: A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 1998; 69: 17-22.
10. Topuz E, Eralp Y, Saglam S, et al: Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front line therapy for epithelial ovarian cancer. Gynecol Oncol 2004; 92: 147-151.
11. Tarraza HM, Boyce CR, Smith WG, et al: Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol 1993; 50: 287-290.
12. Dedrick RL, Myers CE, Bungay PM, et al: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-9.
13. Dedrick RL: Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12: 1-6.
14. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
15. Markmann M: Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Crit Rev Oncol Hematol 2001; 38: 171-175.
16. Markmann M, Brady MF, Spirtos NM, et al: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-2624.
17. Markman M: Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998; 25: 356-360.
18. Markman M: Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev Anticancer Ther 2001; 1: 142-148.
19. Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H: Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res 2009; 155: 142-146.
20. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel- based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
21. Micha JP, Goldstein BH, Graham C, et al: Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology 2006; 71: 49-53.
22. Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Hu JC, Markman M: Experience with singleagent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005; 96: 132-135.
23. Skinner EN, Boruta DM, Gehrig PA, Boggess JF, Fowler WC Jr, Van Le L: Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended followup. Gynecol Oncol 2005; 98: 59-62.
24. Eastern Cooperative Group: Cancer Therapy Evaluation Program, Common Toxicity Criteria, version 2.0. Bethesda, DCTD, NCI, NIH, DHHS, 1999.
25. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. J Clin Oncol 2004; 22: 2635-2642.
26. Bolis G, Danese S, Tateo S, et al: Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006; 16(suppl 1):74-78.
27. Rocconi RP, Straughn JM Jr, Leath CA, et al: Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist 2006; 11: 336-341.
28. DiSilvestro PA, Fisher M, Pearl ML, et al: Pilot phase 2 trial of 4 months of maintenance pegylated liposomal doxorubicin in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. Gynecol Obstet Invest 2007; 63: 1-6.
29. Lee SJ, Lee JW, Min JA, et al: A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. Int J Gynecol Cancer 2006; 16: 95-100.
30. Jaaback K, Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006;CD005340.